NASH-fo­cused Akero Ther­a­peu­tics ex­tends its run­way by an­oth­er year with Pfiz­er's help

Two years ago, Akero Ther­a­peu­tics laid out what one an­a­lyst called the “best-in-class NASH da­ta so far” in a field lit­tered with tri­al fail­ures and am­bigu­ous read­outs. Fol­low­ing those in­ter­im Phase II re­sults, Akero em­barked on a larg­er Phase II tri­al that is sup­posed to re­port out lat­er this year.

But things weren’t look­ing up for the San Fran­cis­co-based biotech when it re­vealed in its Q1 earn­ings re­port that it had just a year and a half of cash left — not enough to push its drug in­to piv­otal Phase III clin­i­cal tri­als that would sup­port an FDA ap­proval.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER